01—Abstract
Summary
Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (INSM) reported 2023 product revenues, net of $305.2 milliona, up from $245.4 million in 2022, driven by ARIKAYCE sales in the US, Japan and Europe.
The company's only approved product is ARIKAYCE, which received accelerated approval in the US in September 2018 and is also approved in Europe and Japan. Net loss widened to $749.6 millionb in 2023 from $481.5 million in 2022, with R&D expenses rising to $571.0 million (including $86.7 million of non-cash asset acquisition costs for the Adrestia and Vertuis acquisitions) and SG&A rising to $344.5 million. Accumulated deficit reached $3.4 billion, and shareholders' equity was negative $331.9 million at year-end.
The company stated that cash and cash equivalents of $482.4 millionc and marketable securities of $298.1 million are sufficient to fund operations for at least the next 12 months. The filing's near-term value drivers are pipeline readouts and regulatory steps. Topline data from the Phase 3 ASPEN trial of brensocatib in bronchiectasis are anticipated in the latter half of the second quarter of 2024, and topline PH-ILD data for TPIP are expected in the second quarter of 2024.
ARIKAYCE's full US approval depends on the confirmatory ARISE and ENCORE trials, with ENCORE topline data anticipated in 2025 and FDA feedback on the PRO endpoint expected in the first half of 2024. Leverage increased materially in October 2022 through a $350 milliond senior secured Term Loan with Pharmakon and a $150 million Royalty Financing Agreement with OrbiMed, alongside $800 million of convertible senior notes outstanding.
Risk concentration is significant. The company's three largest customers accounted for 88% of total gross product revenue in 2023, and the filing notes ARIKAYCE's full approval, pricing and reimbursement, and competition from other inhaled and DPP1 inhibitor programs as key uncertainties.
02—Key points
Key Highlights
- Product revenues, net rose to $305.2 million in 2023 from $245.4 million in 2022, with US revenue of $224.2 million, Japan $65.7 million, and Europe and rest of world $15.3 million.
- Net loss was $749.6 million in 2023 versus $481.5 million in 2022; R&D expenses were $571.0 million and SG&A expenses were $344.5 million.
- Cash and cash equivalents of $482.4 million plus marketable securities of $298.1 million at December 31, 2023, down from $1,074.0 million in cash at year-end 2022; the company states this is sufficient for at least the next 12 months.
- Total shareholders' deficit was $331.9 million at December 31, 2023, versus equity of $88.0 million a year earlier, with an accumulated deficit of $3.4 billion.
- Key 2024 catalysts include ASPEN (brensocatib, bronchiectasis) topline data expected in the latter half of Q2 2024 and TPIP PH-ILD topline data expected in Q2 2024; ENCORE topline data for ARIKAYCE are anticipated in 2025.
- Debt includes a $350 million senior secured Term Loan (SOFR plus 7.75% margin, 2.5% floor, maturing October 2027), a $150 million Royalty Financing Agreement with OrbiMed, and $800 million face value of convertible notes.
- The three largest customers accounted for 88% of total gross product revenue in 2023, and ARIKAYCE is the company's only approved product.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 22, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $305.21M$245.36M | +24.4% |
| Cost of Revenue | $65.57M$55.13M | +19.0% |
| Gross Profit | $239.63M$190.23M | +26.0% |
| R&D Expenses | $571.01M$397.52M | +43.6% |
| SG&A Expenses | $344.50M$265.78M | +29.6% |
| Operating Expenses | $1.01B$702.68M | +44.4% |
| Operating Income | -$709.63M-$457.32M | −55.2% |
| Interest Expense | $81.69M$26.45M | +208.9% |
| Net Income | -$749.57M-$481.53M | −55.7% |
| EPS (Basic) | $-5.34$-3.91 | −36.6% |
| EPS (Diluted) | $-5.34$-3.91 | −36.6% |
| Shares Outstanding (Basic) | 140.43M123.03M | +14.1% |
| Shares Outstanding (Diluted) | 140.43M123.03M | +14.1% |
05—Questions
Frequently Asked Questions
What drove the growth in product revenue in 2023?
Product revenues, net increased $59.9 million, or 24.4%, to $305.2 million, as a result of growth in ARIKAYCE sales in the US, Japan, and Europe and the rest of the world. US revenue rose 20.5%, Japan rose 16.3%, and Europe and rest of world revenue increased from $2.9 million to $15.3 million.
Why did R&D expenses increase so sharply?
R&D expenses increased $173.5 million to $571.0 million. The filing attributes $86.7 million to one-time, non-cash asset acquisition costs for the Adrestia and Vertuis acquisitions, $46.3 million to higher compensation and stock-based compensation from increased headcount, and $21.6 million to higher clinical development spending for the ASPEN, ARIKAYCE, and TPIP trials.
Is ARIKAYCE fully approved, and what is required for full approval in the US?
ARIKAYCE received accelerated approval in the US in September 2018 under the LPAD pathway. Full approval depends on a post-marketing confirmatory trial program consisting of the ARISE and ENCORE trials. ARISE reported positive topline results in September 2023, and the company has proposed the QOL-B respiratory domain PRO as the primary endpoint for ENCORE, pending FDA feedback expected in the first half of 2024. The filing notes the trial completion timetable agreed with the FDA has been delayed.
How is the company financing its operations and what are the debt obligations?
In October 2022 the company entered into a $350 million Term Loan with Pharmakon maturing October 19, 2027, and received $150 million from OrbiMed under a Royalty Financing Agreement equal to 4% of ARIKAYCE global net sales before September 1, 2025 and 4.5% thereafter, plus 0.75% of brensocatib global net sales if approved. The company also has $225 million of 1.75% convertible notes due 2025 and $575 million of 0.75% convertible notes due 2028. The company raised net proceeds of $152.2 million through its at-the-market program in 2023.
What are the main risks highlighted for investors?
The filing highlights dependence on ARIKAYCE as the only approved product, market acceptance and reimbursement pressures (including a 9.4% prospective price decrease in Japan in 2023), the outcome of the ARISE and ENCORE trials, the ASPEN and TPIP readouts, reliance on third-party manufacturers such as Resilience and PARI, concentration in three customers representing 88% of gross product revenue, a history of operating losses, and covenant restrictions under its debt agreements.
06—Continue